ETELCALCETIDE
| Brand name | PARSABIV |
|---|---|
| Active ingredient | ETELCALCETIDE |
| Strength | 5MG/ML (5MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | February 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11162500 | June 2034 | product |
| 9820938 | June 2034 | product |
| 11959486 | June 2034 | product |
| 10344765 | June 2034 | product |
| 8999932 | February 2031 | substance, product |
| 9278995 | July 2030 | substance |
| 8377880 | July 2030 | substance, product |
| 9701712 | July 2030 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.